ChroMedX Announces Appointment of Ash Kaushal as President and CEO
Toronto, Ontario--(Newsfile Corp. - July 26, 2016) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and Point-of-care Testing (POCT) technologies is pleased to announce the appointment of Ash Kaushal as the Company's new President and CEO, effective immediately. Mr. Kaushal has over 25 years of experience in product development in the medical, defence, safety and nuclear industries. Mr. Kaushal has held Vice President and senior level...
2016-07-26 6:00 AM EDT
ChroMedX Reports on HemoPalm Development
Toronto, Ontario--(Newsfile Corp. - April 29, 2016) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and Point-of-care Testing technologies is pleased to report on the Company's HemoPalm development programme. During the first four months of 2016, ChroMedX focused on refining the HemoPalm cartridge design through machining, and developing essential components of the HemoPalm analyzer. "We have made significant progress so far in 2016...
2016-04-29 4:20 PM EDT
ChroMedX Corp. Engages Conductive Technologies Inc. for Biosensor Development Programme
Toronto, Ontario--(Newsfile Corp. - April 20, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of Conductive Technologies Inc. (CTI) of York, Pennsylvania to assist with biosensor development on the Company's HemoPalm technology. ChroMedX has previously reported on the collaboration with Polygenesis on the development of the biosensor system and associated...
2016-04-20 4:15 PM EDT
ChroMedX Corp. Extends Expiry Date of Certain Warrants
Toronto, Ontario--(Newsfile Corp. - February 22, 2016) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) announces that, in accordance with CSE policies, it intends to extend the expiry date of an aggregate of 8,572,500 previously issued warrants (the "Warrants"). The Warrants were originally issued between July 7, 2014 and September 22, 2014, with original expiry dates ranging from March 5, 2016 to July 7, 2016. As a...
2016-02-22 3:17 PM EST
ChroMedX Completes Proof-of-Concept CO-oximetry and Bilirubin Prototype Development
Toronto, Ontario--(Newsfile Corp. - December 11, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) devices is pleased to report the development of a proof-of-concept prototype of the Company's HemoPalmTM analyzer and associated cartridge for measuring CO-oximetry and bilirubin*. The prototype analyzer uses the same light source and spectrophotometer that will be used in the final HemoPalmTM...
2015-12-11 4:15 PM EST
ChroMedX Engages Hochuen International Corp. for Improved Prototype Cartridge Production
Toronto, Ontario--(Newsfile Corp. - December 8, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that it has engaged Hochuen International Corp. to produce an enhanced version of its prototype HemoPalm cartridges. ChroMedX Corp. has entered into a development agreement with Hochuen International Corp. to produce the enhanced version of its HemoPalm cartridges by machining as...
2015-12-08 4:10 PM EST
ChroMedX Corp. Announces Closing of First Tranche of Private Placement
Toronto, Ontario--(Newsfile Corp. - October 16, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement (the "Offering"), pursuant to which the Company issued and sold an aggregate of 1,750,000 units (each, a "Unit") of the Company at a price of CDN$0.20 per Unit for aggregate gross...
2015-10-16 6:40 PM EDT
ChroMedX Corp. Awarded New United States Patent on Ultra Filtration Technology
Toronto, Ontario--(Newsfile Corp. - October 14, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded a United States patent on its Ultra Filtration technology. ChroMedX was awarded US Pat. No. 9,162,186, entitled "Sample Filtration Assembly". This patent is related to manual ultrafiltration cartridges, and while related to two recently...
2015-10-14 4:09 PM EDT
ChroMedX Corp. Announces Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - October 9, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it intends to complete a non-brokered private placement (the "Offering") for gross proceeds of up to CDN$800,000 through the issuance of up to 4,000,000 units (each a "Unit") at a price of CDN$0.20 per Unit. Each Unit will be comprised of one common share of the Company (a...
2015-10-09 8:15 PM EDT
ChroMedX Corp. Awarded Two New Patents on Ultra-Filtration Technology
Toronto, Ontario--(Newsfile Corp. - September 30, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that the Company has been awarded two additional Canadian patents on its Automated Ultra Filtration (AUF) technology. These patents demonstrate the novelty, inventiveness and usefulness of the AUF technology, and are listed below: 1. CA No. 2,876,445 entitled "AUTOMATED...
2015-09-30 4:07 PM EDT
ChroMedX Callaborates with Biointerfaces Institute and Receives Grant
Toronto, Ontario--(Newsfile Corp. - September 16, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce that it has entered into a collaboration with Dr. Leyla Soleymani of the Biointerfaces Institute of McMaster University and received an Engage Grant from NSERC (Natural Sciences and Engineering Research Council of Canada) to further HemoPalmTM biosensor development. Dr....
2015-09-16 4:07 PM EDT
ChroMedx Reports Testing of Key HemoPalm Analyzer Component
Toronto, Ontario--(Newsfile Corp. - September 8, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report that testing has commenced on the key spectroscopic component of the Analyzer of HemoPalmTM blood analysis device. The spectroscopic analysis of blood samples is a key aspect of the HemoPalm system which significantly differentiates it from other point-of-care blood analyzers and...
2015-09-08 4:25 PM EDT
ChroMedX Announces Completion of HemoPalm(TM) Prototype Cartridge
Toronto, Ontario--(Newsfile Corp. - September 4, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to report the completion of the HemoPalm™ System Prototype Cartridge. In conjunction with the previously announced ENGAGE grant with McMaster University's Manufacturing Research Institute (MMRI), the Company has completed the fabrication of the prototype HemoPalm™ cartridge, a key...
2015-09-04 4:30 PM EDT
ChroMedX Engages Polygenesis Corporation for Completion of HemoPalm(TM) Alpha
Toronto, Ontario--(Newsfile Corp. - September 2, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) is pleased to announce the engagement of technology development and prototyping firm Polygenesis Corporation to continue the development of the HemoPalm™ biosensor array, a fundamental component of the HemoPalm™ system. Polygenesis will build on the initial work carried out by Aline Inc. and complete...
2015-09-02 4:30 PM EDT
ChroMedX Submits PCT Patent Application for HemoPalm(TM) Blood Analysis System
Toronto, Ontario--(Newsfile Corp. - August 28, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a PCT (Patent Cooperation Treaty) Patent Application pertaining to the HemoPalm™ Cartridge and Analyzer system called "Joint Spectroscopic and Biosensor System for Point-of-Care Testing" (PCT/CA2015/050455). PCT/CA2015/050455 has the potential to...
2015-08-28 4:30 PM EDT
ChroMedX Corp. Announces OTCQB Listing
Toronto, Ontario--(Newsfile Corp. - August 4, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that its common shares recently commenced trading on the OTCQB®, under the symbol "MNLIF". Real-time quotes and market information on the Company are available at http://www.otcmarkets.com/stock/MNLIF/quote "We are very pleased to be listed on the OTCQB and to have our shares...
2015-08-04 2:02 PM EDT
ChroMedX Corp. Closes Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - July 10, 2015) - ChroMedX Corp. (CSE: CHX) (the "Company") is pleased to announce that it has completed its previously announced non-brokered private placement (the "Offering") for gross proceeds of CDN[$1,148,681.50] through the issuance of [9,189,452] units (each a "Unit") at a price of CDN$0.125 per Unit. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"), each Warrant...
2015-07-10 4:10 PM EDT
ChroMedX Announces Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - July 7, 2015) - ChroMedX Corp. (CSE: CHX) (the "Company" or "ChroMedX") would like to announce that it intends to complete a non-brokered private placement (the "Offering") for gross proceeds of up to CDN$1,200,000 through the issuance of up to 9,600,000 units (each a "Unit") at a price of CDN$0.125 per Unit. Each Unit will be comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"), each Warrant...
2015-07-07 4:15 PM EDT
ChroMedX Welcomes Dr. Nick Smit to Biosensor Development Team
Toronto, Ontario--(Newsfile Corp. - March 25, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Dr. Nick Smit as part of the HemoPalm biosensor development team. Dr. Nick Smit received his Ph.D. in Analytical Chemistry from the University of Delaware and began his career at i-Stat in Princeton, New Jersey and later Ottawa, Ontario where he rose to the...
2015-03-25 4:49 PM EDT
ChroMedX Appoints Dr. Robert Smyth to Technical Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 24, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the appointment of anesthesiologist Dr. Robert Smyth to the Company's Technical Advisory Board. Dr. Smyth completed his MD from the University of Calgary and his anesthesia residency at the University of Toronto. He is an anesthesiologist at Southlake Regional Health Centre in...
2015-03-24 4:16 PM EDT